2023
Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study
Zeng H, Xu M, Xie Y, Nawrocki S, Morze J, Ran X, Shan T, Xia C, Wang Y, Lu L, Yu X, Azeredo C, Ji J, Yuan X, Curi-Quinto K, Liu Y, Liu B, Wang T, Ping H, Giovannucci E. Racial/ethnic disparities in the cause of death among patients with prostate cancer in the United States from 1995 to 2019: a population-based retrospective cohort study. EClinicalMedicine 2023, 62: 102138. PMID: 37593228, PMCID: PMC10430154, DOI: 10.1016/j.eclinm.2023.102138.Peer-Reviewed Original ResearchCause of deathProstate cancerEthnic disparitiesAI/ANsCohort studyCumulative incidenceDiagnostic periodPopulation-based retrospective cohort studyPopulation-based cancer registry dataPopulation-based longitudinal cohort studyRetrospective cohort studyCause-specific deathProstate cancer survivorsEnd Results ProgramCox regression modelLongitudinal cohort studyCancer registry dataPrimary prostate cancerHospitals Clinical Medicine DevelopmentBeijing Municipal AdministrationEthnic groupsBlack-White disparitiesCause mortalityWhite patientsBlack patients
2022
Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer
Han R, Yang H, Li Y, Ling C, Lu L. Valeric acid acts as a novel HDAC3 inhibitor against prostate cancer. Medical Oncology 2022, 39: 213. PMID: 36175803, PMCID: PMC9522682, DOI: 10.1007/s12032-022-01814-9.Peer-Reviewed Original ResearchConceptsProstate cancer cellsProstate cancerHDAC3 inhibitorCancer cellsCancer-related deathAnti-cancer effectsVivo mouse modelAnti-cancer efficacyAnti-cancer activityMouse modelNew agentsSecond causeHDAC inhibitorsCancerNormal cellsInhibitorsValeric acidCellsCASP3 activityCulture systemDiseaseChemosensitizers
2014
Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia
Setiawan VW, Schumacher F, Prescott J, Haessler J, Malinowski J, Wentzensen N, Yang H, Chanock S, Brinton L, Hartge P, Lissowska J, Park SL, Cheng I, Bush WS, Crawford DC, Ursin G, Horn-Ross P, Bernstein L, Lu L, Risch H, Yu H, Sakoda LC, Doherty J, Chen C, Jackson R, Yasmeen S, Cote M, Kocarnik JM, Peters U, Kraft P, De Vivo I, Haiman CA, Kooperberg C, Le Marchand L. Cross-cancer pleiotropic analysis of endometrial cancer: PAGE and E2C2 consortia. Carcinogenesis 2014, 35: 2068-2073. PMID: 24832084, PMCID: PMC4146418, DOI: 10.1093/carcin/bgu107.Peer-Reviewed Original ResearchConceptsEndometrial cancer riskEndometrial cancerCancer riskSingle nucleotide polymorphismsEndometrial Cancer ConsortiumEndometrial cancer casesBody mass indexProstate cancer riskMultiple cancer sitesEvidence of heterogeneityMass indexCancer sitesProstate cancerBonferroni-corrected P valueCancer casesCancer-associated single nucleotide polymorphismsCancer ConsortiumGenome-wide association studiesCancerStatistical significanceP-valueEpidemiologyRiskBiological mechanismsEuropean ancestry
2011
Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries
Zhu G, Chen Y, Zhu Z, Lu L, Bi X, Deng Q, Chen X, Su H, Liu Y, Guo H, Zheng T, Yu H, Zhang Y. Risk of second primary cancer after treatment for esophageal cancer: a pooled analysis of nine cancer registries. Diseases Of The Esophagus 2011, 25: 505-511. PMID: 22067063, DOI: 10.1111/j.1442-2050.2011.01273.x.Peer-Reviewed Original ResearchConceptsStandardized incidence ratiosEsophageal cancer survivorsSecond primary cancerSecond cancersEsophageal cancerPrimary cancerCancer survivorsProstate cancerCancer riskEnd Results ProgramEsophageal cancer patientsAssociation of radiotherapySecond cancer riskMost risk estimatesCancer RegistryIncidence ratiosDecreased riskPatient survivalResults ProgramPooled analysisCancer patientsLung cancerClinical trialsSecondary cancersGeneral population